Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. [electronic resource]
Producer: 20200820ISSN:- 1946-6242
- Antineoplastic Agents -- toxicity
- CRISPR-Cas Systems -- genetics
- Cell Line, Tumor
- Clinical Trials as Topic
- Clone Cells
- Cyclin-Dependent Kinases -- antagonists & inhibitors
- Drug Resistance, Neoplasm -- drug effects
- Gene Knockout Techniques
- Genome, Human
- Humans
- Molecular Targeted Therapy
- Quinolones -- pharmacology
- RNA Interference -- drug effects
- Up-Regulation -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.